Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Lonsurf

- PMLiVE

Pfizer’s Braftovi combination therapy shows positive results for colorectal cancer

Colorectal cancer is the third most common cancer globally, with approximately 1.8 million people diagnosed in 2022

- PMLiVE

Johnson & Johnson’s Rybrevant shows positive effects in difficult-to-treat colorectal cancer

Colorectal cancer accounts for around 10% of all cancer cases globally, with an increase in diagnoses in younger people

- PMLiVE

FDA unveils new voucher programme to accelerate drug review process

The programme is designed to reduce the review time for companies supporting US national interests

- PMLiVE

Pfizer shares ‘unprecedented’ survival results for Braftovi in colorectal cancer

Around 154,270 people are expected to be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

Pfizer gains rights to 3SBio’s investigational bispecific antibody in deal worth over $6bn

The candidate is in clinical development for colorectal cancer, lung cancer and gynaecological tumours

- PMLiVE

BMS receives NICE recommendation for immunotherapy combination in colorectal cancer

Approximately 44,000 people are diagnosed with colorectal cancer in the UK every year

- PMLiVE

BMS granted FDA approval for immunotherapy combination in colorectal cancer

More than 154,000 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

FDA approves Bavarian Nordic’s chikungunya vaccine for individuals aged from 12 years

The mosquito-borne viral disease has been reported across many popular travel destinations

- PMLiVE

Roche’s Evrysdi tablet formulation granted FDA approval for spinal muscular atrophy

The progressive neuromuscular disease affects approximately one in every 10,000 babies globally

- PMLiVE

Pfizer announces positive phase 3 results for Braftovi regimen in colorectal cancer

An estimated 154,270 people will be diagnosed with cancer of the colon or rectum in the US this year

- PMLiVE

BMS presents promising data for immunotherapy combination in phase 3 colorectal cancer trial

Over 154,000 cases of colorectal cancer are expected to be diagnosed in the US in 2025

- PMLiVE

Pfizer shares positive late-stage results for Braftovi regimen in colorectal cancer

The combination was approved in the US last month to treat BRAF V600E-mutant disease

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links